A glutamatergic model of ECT-induced memory dysfunction

Harvard Review of Psychiatry

Volumn 5, Issue 6, 1998, Pages 307-317

  Chamberlin, Eric ^a   Tsai, Guochuan E ^b,c  

^a INSTITUTE OF LIVING   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; DIZOCILPINE; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

AMNESIA; CATION TRANSPORT; ELECTROCONVULSIVE THERAPY; HUMAN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEIZURE; WATER TRANSPORT;

EID: 0031944820     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229809003579     Document Type: Review

References (118)

1. Summers WK, Robins E, Reich T. The natural history of acute organic mental syndrome after bilateral electroconvulsive therapy. Biol Psychiatry 1979;14:905-12.
2. Sackeim HA, Portnoy S, Neeley P, Steif BL, Decina P, Malitz S. Cognitive consequences of low-dosage electroconvulsive therapy. Ann N Y Acad Sci 1986;462:326-40.
3. Calev A, Cohen R, Tubi N, Nigal D. Disorientation and bilateral moderately suprathreshold titrated ECT. Convuls Ther 1991;7:99-110.
4. Daniel WF, Crovitz HF. Recovery of orientation after electroconvulsive therapy. Acta Psychiatr Scand 1982;66:421-8.
5. Figiel GS, Coffey CE, Djang WT. Brain magnetic resonance imaging findings in ECT-induced delirium. J Neuropsychiatry Clin Neurosci 1990;2:53-8.
6. Steif BL, Sackeim HA, Portnoy S, Decina P, Malitz S. Effects of depression and ECT on anterograde memory. Biol Psychiatry 1986;21:921-30.
7. Calev A, Nigal D, Shapira B, Tubi N, Chazan S, Ben-Yehuda Y, et al. Early and long-term effects of electroconvulsive therapy and depression on memory and other cognitive functions. J Nerv Ment Dis 1991;179:526-33.
8. Squire LR, Slater PC, Miller PL. Retrograde amnesia and bilateral electroconvulsive therapy. Arch Gen Psychiatry 1981;38:89-95.
9. Squire LR. Memory and brain. New York: Oxford University Press, 1987.
10. Squire LR, Slater PC. Electroconvulsive therapy and complaints of memory dysfunction: a prospective three-year follow-up study. Br J Psychiatry 1983;142:1-8.
11. Freeman CPL, Kendell RE. ECT I: Patients' experiences and attitudes. Br J Psychiatry 1980;137:8-16.
12. Taylor JR, Tompkins R, Demers R, Anderson D. Electroconvulsive therapy and memory dysfunction: is there evidence for prolonged defects? Biol Psychiatry 1982;17:1169-93.
13. Weeks D, Freeman CPL, Kendell RE. ECT III: Enduring cognitive deficits? Br J Psychiatry 1980;137:26-37.
14. Weiner RD, Rogers HJ, Davidson JR, Kahn EM. Effects of electroconvulsive therapy upon brain electrical activity. Ann N Y Acad Sci 1986;462:270-81.
15. Weiner RD, Rogers HJ, Davidson JR, Squire LR. Effects of stimulus parameters on cognitive side effects. Ann N Y Acad Sci 1986;462:315-25.
16. D'Elia G. Unilateral electroconvulsive therapy. Acta Psychiatr Scand Suppl 1970;215:1-98.
17. Lancaster NP, Steinert RR, Frost I. Unilateral electroconvulsive therapy. J Ment Sci 1958;104:221-7.
18. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive side effects of electroconvulsive therapy. N Engl J Med 1993;328:839-46.
19. Shapira B, Calev A, Lerer B. Optimal use of electroconvulsive therapy: choosing a treatment schedule. Psychiatr Clin North Am 1991;14:935-46.
20. Sackeim H, Decina P, Prohovnik I, Malitz S. Seizure threshold in electroconvulsive therapy: effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry 1987;44:355-60.
21. Sackeim HA, Devanand DP, Prudic J. Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiatr Clin North Am 1991;14:803-43.
22. Krueger RB, Sackeim HA, Gamzu ER. Pharmacological treatment of the cognitive side effects of ECT: a review. Psychopharmacol Bull 1992;28:409-24.
23. Levin Y, Elizur A, Korczyn AD. Physostigmine improves ECT-induced memory disturbances. Neurology 1987;37:871-5.
24. Andrade C, Rao NS, Sekhar RV, Rani MA, Venkataraman BV. Relationship between rate of administration of electroconvulsive shocks and rate of learning in rats: implications for the practice of ECT. Convuls Ther 1994;10:206-11.
25. Anwyl R, Walshe J, Rowan M. Electroconvulsive treatment reduces long-term potentiation in rat hippocampus. Brain Res 1987;435:377-9.
26. Stewart C, Jeffery K, Reid I. LTP-like synaptic efficacy changes following electroconvulsive stimulation. Neuroreport 1994;5:1041-4.
27. Stewart C, Reid I. Electroconvulsive stimulation and synaptic plasticity in the rat. Brain Res 1993;620:139-41.
28. Stewart CA, Reid IC. Ketamine prevents ECS-induced synaptic enhancement in rat hippocampus. Neurosci Lett 1994;178:11-1.
29. Cotman CW, Monaghan DT. Anatomical organization of excitatory amino acid receptors and their properties. Adv Exp Med Biol 1986;203:237-52.
30. Gloor P. Epilepsy: relationships between electrophysiology and intracellular mechanisms involving second messengers and gene expression. Can J Neurol Sci 1989;16:8-21.
31. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989;29:365-402.
32. Collingridge GL, Bliss TYP. NMDA receptors: their role in long-term potentiation. Trends Neurosci 1987;10:288-93.
33. Cotman GW, Monaghan DT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988;11:61-80.
34. Harris EW, Ganong AH, Cotman CW. Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res 1984;323:132-7.
35. Nicoll RA, Kauer JA, Malenka RC. The current excitement in long-term potentiation. Neuron 1988;1:97-103.
36. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969;164:719-21.
37. Olney JW. Inciting excitotoxic cytocide among central neurons. Adv Exp Med Biol 1986;203:631-45.
38. McDonald JW, Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 1990;15:41-70.
39. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23:1261-76.
40. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-95.
41. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991;88:6368-71.
42. 2+-activated mechanisms in cell killing. Drug Metab Rev 1989;20:193-201.
43. Siman R, Noszek JC, Kergerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci 1989;9:1579-90.
44. Olney JW. Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol 1990;30:47-71.
45. Devanand DP, Dwork AJ, Hutchinson ER, Bolwig TG, Sackeim HA. Does ECT alter brain structure? Am J Psychiatry 1994;151:957-70.
46. Coffey CE, Weiner RD, Djang WT, Figiel GS, Soady SAR, Patterson LJ, et al. Brain anatomic effects of electroconvulsive therapy: a prospective magnetic resonance imaging study. Arch Gen Psychiatry 1991;48:1013-21.
47. Wasterlain CG, Fujikawa DG, Penix L, Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993;34(suppl):S37-53.
48. Halgren E, Stapleton J, Domalski P, Swartz BE, Delgado-Escueta AV, Walsh GO, et al. Memory dysfunction in epilepsy patients as a derangement of normal physiology. Adv Neurol 1991;55:385-410.
49. Mathern GW, Leite JP, Pretorius JK, Quinn B, Peacock WJ, Babb TL. Children with severe epilepsy: evidence of hippocampal neuron losses and aberrant mossy fiber sprouting during postnatal granule cell migration and differentiation. Dev Brain Res 1994;78:70-80.
50. Meldrum B. Physiological changes during prolonged seizures and epileptic brain damage. Neuropaediatric 1978;9:203-12.
51. Cavazos JE, Das I, Sutula TP. Neuronal loss induced in limbic pathways by kindling: evidence for induction of hippocampal sclerosis by repeated brief seizures. J Neurosci 1994;14:3106-21.
52. Sutula TP, Cavazos JE, Woodard AR. Long-term structural and functional alterations induced in the hippocampus by kindling: implications for memory dysfunction and the development of epilepsy. Hippocampus 1994;4:254-8.
53. Sommer W. Erkrankung des Ammonshorns als aetiologisches Moment der Epilepsie. Arch Psychiatrie Nervenkrankh 1880;10:631-75.
54. Delaney RC, Rosen AJ, Mattson RH, Novelly RA. Memory function in focal epilepsy: a comparison of non-surgical, unilateral temporal lobe and frontal lobe samples. Cortex 1980;16:103-17.
55. Delaney RC, Prevey ML, Mattson RH. Short term retention with lateralized temporal lobe epilepsy. Cortex 1986;22:591-600.
56. Loiseau P, Strube E, Broustet D, Battellochi S, Gomeni C, Morselli PL. Learning impairment in epileptic patients. Epilepsia 1983;24:183-92.
57. Margerison JH, Corsellis JAN. Epilepsy and the temporal lobes: a clinical, electroencephalographic and neuropathological study of the brain in epilepsy, with particular reference to the temporal lobes. Brain 1966;89:499-530.
58. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985;14:375-403.
59. Mouritze Dam A. Hippocampal neuron loss in epilepsy and after experimental seizures. Acta Neurol Scand 1982;66:601-42.
60. Sloviter RS, Dempster DW. "Epileptic" brain damage is replicated qualitatively in the rat hippocampus by central injection of glutamate or aspartate but not by GABA or acetylcholine. Brain Res Bull 1985;15:39-60.
61. Olney JW, DeGubareff T, Sloviter RS. "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path, II: Ultrastructural analysis of acute hippocampal pathology. Brain Res Bull 1983;10:699-712.
62. Sloviter RS. "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path, I: Acute electrophysiological and light microscopic studies. Brain Res Bull 1983;10:675-97.
63. Laursen H, Gjerris A, Bolwig TG, Barry DI. Cerebral edema and vascular permeability to serum proteins following electroconvulsive shock in rats. Convuls Ther 1991;7:237-44.
64. Petito CK, Schaefer JA, Plum F. Ultrastructural characteristics of the brain and blood-brain barrier in experimental seizures. Brain Res 1977;127:251-67.
65. Scott AI, Douglas RH, Whitfield A, Kendell RE. Time course of cerebral magnetic resonance changes after electroconvulsive therapy. Br J Psychiatry 1990;156:551-3.
66. Tsai G, Ragan P, Chang R, Linnoila VMI, Coyle JT. Increased glutamatergic neurotransmission and oxidative stress during alcohol withdrawal. Am J Psychiatry [In press].
67. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992;12:4427-36.
68. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993;33:403-7.
69. Goldberg MP, Choi DW. Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. J Neurosci 1993;13:3510-24.
70. Weiss JH, Hartley DM, Koh J, Choi DW. The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. Science 1990;247:1474-7.
71. Izumi Y, Benz AM, Clifford DB, Zorumski CF. Nitric oxide inhibitors attenuate N-methyl-D-aspartate excitotoxicity in rat hippocampal slices. Neurosci Lett 1992;135:227-30.
72. Monyer H, Hartley DM, Choi DW. 21-Aminosteroids attenuate excitotoxic neuronal injury in cortical cell cultures. Neuron 1990;5:121-6.
73. Kaku DA, Goldberg MP, Choi DW. Antagonism of non-NMDA receptors augments the neuroprotective effect of NMDA receptor blockade in cortical cultures subjected to prolonged deprivation of oxygen and glucose. Brain Res 1991;554:344-7.
74. Coyle JT. Excitotoxins. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven, 1987:333-40.
75. Olney JW, Collins RC, Sloviter RS. Excitotoxic mechanisms of epileptic brain damage. Adv Neurol 1986;44:857-77.
76. Clifford DB, Olney JW, Benz AM, Fuller TA, Zorumski CF. Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990;31:382-90.
77. Fariello RG, Golden GT, Smith GG, Reyes PF. Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist. Epilepsy Res 1989;3:206-13.
78. Lason W, Simpson JN, McGinty JF. Effects of D-(-)-aminophosphonovalerate on behavioral and histological changes induced by systemic kainic acid. Neurosci Lett 1988;87:23-8.
79. Fujikawa DG. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 1995;36:186-95.
80. Hudson GM, Buterbaugh GG. MK-801 is neuroprotective, but not anticonvulsive, during pilocarpine-facilitated status epilepticus in kindled rats [Abstract]. Soc Neurosci Abstr 1989;15:777.
81. Sloviter RS. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987;235:73-6.
82. Rogers BC, Barnes MI, Mitchell CL, Tilson HA. Functional deficits after sustained stimulation of the perforant path. Brain Res 1989;493:41-50.
83. Ylinen A, Lahtinen H, Sirviö J, Partanen J, Asikainen A, Gulyas A, et al. Behavioural, electrophysiological and histopathological changes following sustained stimulation of the perforant pathway input to the hippocampus: effect of the NMDA receptor antagonist, CGP 39551. Brain Res 1991;553:195-200.
84. Bullock R. Strategies for neuroprotection with glutamate antagonists: extrapolating from evidence taken from the first stroke and head injury studies. Ann N Y Acad Sci 1995;765:272-8.
85. Hamm RJ, O'Dell DM, Pike BR, Lyeth BG. Cognitive impairment following traumatic brain injury: the effect of pro- and post-injury administration of scopolamine and MK-801. Cogn Brain Res 1993;1:223-6.
86. American Psychiatric Association, Task Force on ECT. The practice of ECT: recommendations for treatment, training and privileging. Convuls Ther 1990;6:85-120.
87. Staton RD, Enderle JD, Gerst JW. The electroencephalographic pattern during electroconvulsive therapy, IV: Spectral energy distributions with methohexital, innovar and ketamine anesthesias. Clin Electroencephalogr 1986;17:203-15.
88. Smith DH, Okiyama K, Gennarelli TA, McIntosh TK. Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury. Neurosci Lett 1993;157:211-4.
89. Pfenninger E, Baier C, Claus S, Hege G. Psychometric changes as well as analgesic action and cardiovascular adverse effects of ketamine racemate versus s-(+)-ketamine in subanesthetic doses. Anaesthesist 1994;43(suppl 2):S68-75.
90. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
91. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-36..
92. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989;166:591-2.
93. Trube G, Netzer R. Dextromethorphan: cellular effects reducing neuronal hyperactivity. Epilepsia 1994;35(suppl 5):S62-7.
94. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
95. Fix AS, Wozniak DF, Truex LL, McEwen M, Miller JP, Olney JW. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res 1995;696:194-204.
96. Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem Res 1993;18:1263-9.
97. Hargreaves RJ, Rigby M, Smith D, Hill RG. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br J Pharmacol 1993;110:36-42.
98. Duval D, Roome N, Gauffeny C, Nowicki JP, Scatton B. SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons. Neurosci Lett 1992;137:193-7.
99. Fujikawa DG, Daniels AH, Kim JS. The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Res 1994;17:207-19.
100. Loscher W, Honack D. Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy: comparison with MK-801 and carbamazepine. J Pharmacol Exp Ther 1991;256:432-40.
101. Loscher W, Honack D. Overadditive anticonvulsant effect of memantine and NBQX in kindled rats. Eur J Pharmacol 1994;259:R3-5.
102. Wada Y, Hasegawa H, Nakamura M, Yamaguchi N. The NMDA receptor antagonist MK-801 has a dissociative effect on seizure activity of hippocampal-kindled cats. Pharmacol Biochem Behav 1992;43:1269-72.
103. Sveinbjornsdottir S, Sander JW, Upton D, Thompson PJ, Patsalos PN, Hirt D, et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EEA-494) in patients with epilepsy. Epilepsy Res 1993;16:165-74.
104. Tortella FC, Robles L, Witkin JM, Newman AH. Novel anticonvulsant analogs of dextromethorphan: improved efficacy, potency, duration and side-effect profile. J Pharmacol Exp Ther 1994;268:727-33.
105. Zhou LM, Szendrei GI, Fossom LH, Maccecchini ML, Skolnick P, Otvos L Jr. Synthetic analogues of conantokin-G: NMDA antagonists acting through a novel polyamine-coupled site. J Neurochem 1996;66:620-8.
106. Priestley T, Laughton P, Macaulay AJ, Hill RG, Kemp JA. Electrophysiological characterisation of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324. Neuropharmacology 1996;35:1573-81.
107. Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients: a double-blind cross-over study. Br J Psychiatry 1995;166:241-3.
108. Wong M, Moss RL. Patch-clamp analysis of direct steroidal modulation of glutamate receptor-channels. J Neuroendocrinol 1994;6:347-55.
109. Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 1985;5:1222-7.
110. Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993;47:163-73.
111. Armanini MP, Hutchins C, Stein BA, Sapolsky RM. Glucocorticoid endangerment of hippocampal neurons is NMDA-receptor dependent. Brain Res 1990;532:7-12.
112. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995;152:332-40.
113. Chandler LJ, Newsom H, Sumners C, Crews F, Chronic ethanol exposure potentiates NMDA excitotoxicity in cerebral cortical neurons. J Neurochem 1993;60:1978-81.
114. Kamei J, Igarashi H, Kasuya Y. Modulation by serotonin of glutamate-induced lethality in mice. Res Commun Chem Pathol Pharmacol 1991;74:167-84.
115. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea D, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993;150:1731-3.
116. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, et al. A specific laboratory test for the diagnosis of melancholia: standardization, validation, and clinical utility. Arch Gen Psychiatry 1981;38:15-22.
117. Yehuda R, Boisoneau D, Mason JW, Giller EL. Glucocorticoid receptor number and cortisol excretion in mood, anxiety, and psychotic disorders. Biol Psychiatry 1993;34:18-25.
118. Home RL, Pettinati HM, Menken M, Sugerman AA, Varga E, Wilson GF. Dexamethasone in electroconvulsive therapy: efficacy for depression and post-ECT amnesia. Biol Psychiatry 1984;19:13-27.